Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains
- PMID: 35055136
- PMCID: PMC8780072
- DOI: 10.3390/ijms23020950
Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains
Abstract
Light chain amyloidosis (AL) is caused by the aberrant overproduction of immunoglobulin light chains (LCs). The resulting abnormally high LC concentrations in blood lead to deposit formation in the heart and other target organs. Organ damage is caused not only by the accumulation of bulky amyloid deposits, but extensive clinical data indicate that circulating soluble LCs also exert cardiotoxic effects. The nematode C. elegans has been validated to recapitulate LC soluble toxicity in vivo, and in such a model a role for copper ions in increasing LC soluble toxicity has been reported. Here, we applied microscale thermophoresis, isothermal calorimetry and thermal melting to demonstrate the specific binding of Cu2+ to the variable domain of amyloidogenic H7 with a sub-micromolar affinity. Histidine residues present in the LC sequence are not involved in the binding, and yet their mutation to Ala reduces the soluble toxicity of H7. Copper ions bind to and destabilize the variable domains and induce a limited stabilization in this domain. In summary, the data reported here, elucidate the biochemical bases of the Cu2+-induced toxicity; moreover, they also show that copper binding is just one of the several biochemical traits contributing to LC soluble in vivo toxicity.
Keywords: copper binding; copper ions; light chain amyloidosis; protein aggregation; soluble toxicity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



References
-
- Benson M.D., Buxbaum J.N., Eisenberg D.S., Merlini G., Saraiva M.J.M., Sekijima Y., Sipe J.D., Westermark P. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis. 2018;25:215–219. doi: 10.1080/13506129.2018.1549825. - DOI - PubMed
-
- Eisele Y.S., Janssen M.E., MA D., Nguyen B., Plate L., Morgan G.J., Reixach N., Buxbaum J.N., Wiseman R.L., Lander G.C., et al. Formation and toxicity of transthyretin (ttr) oligomers in vitro and in patients with familial amyloid polyneuropathy. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2018;14:1123–1124. doi: 10.1016/j.jalz.2018.06.1503. - DOI
-
- Madhivanan K., Greiner E.R., Alves-Ferreira M., Soriano-Castell D., Rouzbeh N., Aguirre C.A., Paulsson J.F., Chapman J., Jiang X., Ooi F.K., et al. Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 2018;115:E7710–E7719. doi: 10.1073/pnas.1801117115. - DOI - PMC - PubMed
-
- Palladini G., Lavatelli F., Russo P., Perlini S., Perfetti V., Bosoni T., Obici L., Bradwell A.R., D’Eril G.M., Fogari R., et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107:3854–3858. doi: 10.1182/blood-2005-11-4385. - DOI - PubMed